

Title (en)
COMPOSITIONS AND METHODS FOR INHIBITING ANGIOGENESIS

Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR UNTERDRÜCKUNG DER ANGIOGENESE

Title (fr)
COMPOSITIONS ET PROCEDES PERMETTANT D'INHIBER L'ANGIOGENESE

Publication
EP 1968565 A4 20091216 (EN)

Application
EP 05784880 A 20050418

Priority
• US 2005013079 W 20050418
• US 56284104 P 20040416

Abstract (en)
[origin: WO2006001888A2] Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is one of the most frequently expressed angiogenic factors in tumors. Development of VEGF antagonists has become an important approach in cancer therapy. The present invention relates to an anti-VEGF strategy wherein VEGF secretion from tumors cells is prevented. The placenta growth factor-1 (PLGF-1), a member of the VEGF family lacking detectable angiogenic activity, preferentially forms intracellular heterodimers with VEGF in cells co-expressing both factors. A retroviral vector was constructed containing human PLGF-I (SEQ ID NO: 1) or VEGF with a C-terminal KDEL (SEQ ID NO: 7) sequence, which is a signal for endoplasmic reticulum (ER)-retention in mammalian cells. Transduction of murine Lewis lung carcinoma (LLC) cells with the PLGF-1-KDEL retroviral vector almost completely abrogated tumor growth and induced tumor dormancy. Consistent with the dramatic anti-tumor effect, most mouse VEGF molecules remain as intracellular VEGF/PLGF-I heterodimers and only a negligible amount of VEGF homodimers are secreted. As a result, in PLGF-1-KDEL (SEQ ID NO: 3) tumors blood vessels remain at very low numbers and lack branching and capillary networks. Gene transfer of a VEGF-KDEL construct into tumor cells likewise produced a dramatic antitumor effect. Thus, the present invention provides compositions and methods for inhibiting secretion of VEGF from cells.

IPC 8 full level
C07K 14/475 (2006.01); **A61K 31/713** (2006.01); **C12N 15/00** (2006.01); **C07H 21/04** (2006.01)

CPC (source: EP US)
A61P 43/00 (2018.01 - EP); **C07K 14/52** (2013.01 - EP US)

Citation (search report)
• [PX] BJORNDAHL MEIT ET AL: "Blockage of VEGF- induced angiogenesis by preventing VEGF secretion", CIRCULATION RESEARCH, vol. 94, no. 11, 11 June 2004 (2004-06-11), pages 1443 - 1450, XP002553705, ISSN: 0009-7330
• [A] JOHANSEN T E ET AL: "C-terminal KDEL-modified cystatin C is retained in transfected CHO cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 172, no. 3, 15 November 1990 (1990-11-15), pages 1384 - 1391, XP024843804, ISSN: 0006-291X, [retrieved on 19901115]
• [A] ERIKSSON A ET AL: "Placenta growth-factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive P1GF-1/VEGF heterodimers", CANCER CELL, CELL PRESS, US, vol. 1, 1 February 2002 (2002-02-01), pages 99 - 108, XP002967596, ISSN: 1535-6108
• [A] VERHEUL H M W ET AL: "VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS INHIBITORS", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 39, no. SUPPL. C, 1 January 2003 (2003-01-01), pages 81 - 93, XP008033177, ISSN: 0025-7656
• [A] SHINKARUK S ET AL: "Vascular Endothelial Cell Growth Factor (VEGF), an emerging target for cancer chemotherapy", CURRENT MEDICINAL CHEMISTRY. ANTI-CANCER AGENTS, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 3, no. 2, 1 March 2003 (2003-03-01), pages 95 - 117, XP009125135, ISSN: 1568-0118

Cited by
US11505610B2; US11807687B2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2006001888 A2 20060105; WO 2006001888 A3 20090423; CN 101426489 A 20090506; EP 1968565 A2 20080917; EP 1968565 A4 20091216; EP 1968565 B1 20151118; US 2008045469 A1 20080221

DOCDB simple family (application)
US 2005013079 W 20050418; CN 200580019894 A 20050418; EP 05784880 A 20050418; US 57859905 A 20050418